Redsun: 97% Chlorantraniliprole technical’s registration was approved

Recently, Nanjing RedSun answered investors' concerns and questions on the investor interactive platform, involving the production capacity and other dynamic of Diquat, Paraquat, Chlorantraniliprole, Glufosinate ammonium and other products. The questions and answers are as follows

Q

Q: "By the end of the year, what is the capacity of Redsun’s Diquat? Are there any more projects under construction?”

A: At present, the company has a total production capacity of 20,000 t/a Diquat dichloride and about 5,000 t/a of Diquat. At present, all of them have been completed and put into production.

Q: What is the progress of the antidote

A:  The antidote of the company's paraquat project is progressing smoothly and is currently applying for related international patents.

Q: "May I ask whether the registration of 97% Chlorantraniliprole has been approved by the state? Which countries have obtained registration of Diquat dichloride? Could you tell me the progress of foreign registration?

A: At present, 97% Chlorantraniliprole of the company has obtained the national approval. Diquat dichloridehas been registered on the market in Paraguay and registration in other countries is under way.

Q:"Is Glufosinate ammonium still going to be produced? Why is the production line taking so long?

A: The company's Glufosinate ammonium project is under construction.

Q: May I ask when Kangkuan plans to start production?

A:  The company's Chlorantraniliprole project is expected to begin production in 2023